Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Cediranib may alter DNA repair capacity
Key clinical point: Researchers have identified novel DNA repair mechanisms that could help guide the development of combination therapies with cediranib.
Major finding: Cediranib provides sensitivity to olaparib through downregulation of the homology-directed DNA repair (HDR) pathway in cancer cells.
Study details: A molecular study exploring the impact of cediranib and olaparib on the HDR pathway.
Disclosures: The study was supported by grant funding from the National Institutes of Health. One of the researchers reported financial affiliations with Trucode Gene Repair, Cybrexa Therapeutics, and Patrys.
Kaplan AR et al. Sci Transl Med. 2019 May 15. doi: 10.1126/scitranslmed.aav4508.